Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials across 4 countries. Studies span Phase 1, Phase 2. Top locations include Salt Lake City, Utah, United States, Beijing, Beijing Municipality, China, Changchun, Jilin, China. Updated daily from ClinicalTrials.gov.


Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trials at a Glance

6 actively recruiting trials for relapsed or refractory b-cell non-hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Salt Lake City, Beijing, and Changchun. Lead sponsors running relapsed or refractory b-cell non-hodgkin lymphoma studies include University of Utah, Autolus Limited, and Excyte Biopharma Ltd.

Browse relapsed or refractory b-cell non-hodgkin lymphoma trials by phase

Treatments under study

About Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Relapsed or Refractory B-cell Non-Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Relapsed or Refractory B-cell Non-Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC155 enrolled3 locationsNCT07439653
Recruiting
Phase 1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 1

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
Autolus Limited30 enrolled8 locationsNCT06173518
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Excyte Biopharma Ltd48 enrolled1 locationNCT06565689
Recruiting
Phase 1

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah24 enrolled1 locationNCT06824701
Recruiting
Phase 2

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Mantle Cell LymphomaMarginal Zone LymphomaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah27 enrolled1 locationNCT06300528